Winton Group’s Summit Therapeutics SMMT Stock Holding History

Winton Group’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-22,400	Closed	-$425K	–	1465
2026 Q1	$425K	Buy	+22,400	New	+$362K	0.01%	754
2025 Q4	–	Sell	-64,900	Closed	-$1.34M	–	1100
2025 Q3	$1.34M	Buy	+64,900	New	+$1.57M	0.05%	334

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Winton Group's SMMT Position: Q2 2026 in Review

Winton Group sold out of Summit Therapeutics (SMMT) in Q2 2026, closing a stake of 22,400 shares — an estimated $425K sold.

Winton Group first reported a position in SMMT in Q3 2025 and held it in 2 quarters. The position peaked at $1.34M in Q3 2025. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

Winton Group reported no remaining Summit Therapeutics position as of Q2 2026 after selling out during the quarter.
Winton Group sold 22,400 Summit Therapeutics shares in Q2 2026, an estimated $425K.
Winton Group first reported a position in Summit Therapeutics in Q3 2025 and held it in 2 quarters.
Winton Group's Summit Therapeutics position peaked at $1.34M in Q3 2025.
242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Winton Group's 13F filing for Q2 2026, filed 7 Aug 2026.